Based on the key measurements obtained from Mereo BioPharma's financial statements, Mereo BioPharma Group is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Mereo BioPharma's Common Stock Total Equity is very stable compared to the past year. As of the 24th of March 2025, Common Stock Shares Outstanding is likely to grow to about 796.3 M, while Short and Long Term Debt Total is likely to drop about 6.5 M. Key indicators impacting Mereo BioPharma's financial strength include:
The financial analysis of Mereo BioPharma is a critical element in measuring its lifeblood. Investors should not minimize Mereo BioPharma's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Mereo BioPharma competes with Terns Pharmaceuticals, PDS Biotechnology, Inozyme Pharma, Hookipa Pharma, and Day One. Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Mereo BioPharma's current stock value. Our valuation model uses many indicators to compare Mereo BioPharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mereo BioPharma competition to find correlations between indicators driving Mereo BioPharma's intrinsic value. More Info.
Mereo BioPharma Group is regarded fifth in return on equity category among its peers. It is regarded fourth in return on asset category among its peers . At this time, Mereo BioPharma's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mereo BioPharma's earnings, one of the primary drivers of an investment's value.
Mereo BioPharma Group Systematic Risk
Mereo BioPharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mereo BioPharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Mereo BioPharma Group correlated with the market. If Beta is less than 0 Mereo BioPharma generally moves in the opposite direction as compared to the market. If Mereo BioPharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mereo BioPharma Group is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mereo BioPharma is generally in the same direction as the market. If Beta > 1 Mereo BioPharma moves generally in the same direction as, but more than the movement of the benchmark.
Mereo BioPharma Thematic Clasifications
Mereo BioPharma Group is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Mereo BioPharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mereo BioPharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Mereo BioPharma growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Mereo BioPharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mereo BioPharma Group. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mereo BioPharma Group based on widely used predictive technical indicators. In general, we focus on analyzing Mereo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mereo BioPharma's daily price indicators and compare them against related drivers.
When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.25)
Revenue Per Share
0.007
Return On Assets
(0.24)
Return On Equity
(0.48)
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.